US2024000473A1PendingUtilityA1

Systems and methods for submucosal tissue separation

Assignee: BOSTON SCIENT SCIMED INCPriority: May 19, 2017Filed: Sep 18, 2023Published: Jan 4, 2024
Est. expiryMay 19, 2037(~10.8 yrs left)· nominal 20-yr term from priority
A61B 17/320016A61L 31/148A61L 31/042A61B 17/00234A61M 5/19A61M 5/285A61B 17/3478G01R 33/0011G01R 33/0017H01F 27/346A61B 18/14A61B 2017/00942A61M 2005/3106A61B 18/082A61B 2018/00982A61L 2400/06A61B 2017/00269A61B 2017/0034A61B 2017/00818A61B 2018/00601A61B 2018/00494A61B 2018/00595
74
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to the field of medical devices generally and specifically, to endoscopic systems and methods for resection of malignant and pre-malignant lesions within the gastrointestinal (GI) tract. In particular, the present disclosure relates to systems and methods for delivering injectable compositions between tissue layers (e.g., between the muscularis and submucosa layers) to elevate and stabilize the lesion for fast and efficient resection.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A system, comprising:
 a delivery device comprising a proximal portion, distal portion, a lumen extending therebetween;   a first injectable composition disposed within the distal portion of the delivery device; and   a second injectable composition disposed within the proximal portion of the delivery device;   wherein the first and second injectable compositions are separated by a barrier member; and   wherein the system is configured to sequentially deliver the first and second injectable compositions.   
     
     
         2 . The system of  claim 1 , wherein the barrier member is configured to rupture above a threshold level of force. 
     
     
         3 . The system of  claim 1 , wherein the barrier member includes a biocompatible or biodegradable material. 
     
     
         4 . The system of  claim 1 , wherein the second injectable composition comprises a hydrophilic polymer selected from the group consisting of acrylate-based polymers, polyurethane-based polymers, polynorbornene-based polymer and polylactide-based polymers. 
     
     
         5 . The system of  claim 1 , wherein the second injectable composition comprises a polysaccharide. 
     
     
         6 . The system of  claim 5 , wherein the polysaccharide is a xanthan gum. 
     
     
         7 . The system of  claim 1 , wherein the delivery device includes a sharpened distal end. 
     
     
         8 . The system of  claim 1 , wherein the delivery device is configured to be delivered through a working channel of an endoscope. 
     
     
         9 . A system, comprising:
 a delivery device comprising a proximal portion, distal portion and lumen extending therebetween;   a first injectable composition disposed within the distal portion of the delivery device;   and a second injectable composition disposed within the proximal portion of the delivery device;   wherein the first and second injectable compositions are separated by a barrier member;   wherein the delivery device is configured to (a) extend through a working channel of an endoscope that comprises a proximal end, a distal end and said working channel such that a distal end of the delivery device extends into tissue beyond the distal end of the endoscope and such that the distal end of the delivery device is positioned between adjacent first and second tissue layers and (b) inject the first and second injectable compositions between the first and second layers; and   wherein the system is configured to sequentially deliver the first and second injectable compositions.   
     
     
         10 . The system of  claim 9 , wherein the barrier member is configured to rupture above a threshold level of force. 
     
     
         11 . The system of  claim 9 , wherein the barrier member includes a biocompatible or biodegradable material. 
     
     
         12 . The system of  claim 9 , wherein the second injectable composition comprises a hydrophilic polymer selected from the group consisting of acrylate-based polymers, polyurethane-based polymers, polynorbornene-based polymer and polylactide-based polymers. 
     
     
         13 . The system of  claim 9 , wherein the second injectable composition comprises a polysaccharide. 
     
     
         14 . The system of  claim 13 , wherein the polysaccharide is a xanthan gum. 
     
     
         15 . The system of  claim 9 , wherein the delivery device includes a sharpened distal end. 
     
     
         16 . system, comprising:
 a delivery device comprising a proximal portion, distal portion, lumen extending therebetween; and a plunger slidably disposed within the lumen;   a first injectable composition disposed within the distal portion of the delivery device;   and a second injectable composition disposed within the proximal portion of the delivery device;   wherein the first and second injectable compositions are separated by a barrier member that is formed of a destructible member that is configured to rupture upon operation of the plunger;   and wherein the system is configured to sequentially deliver the first and second injectable compositions.   
     
     
         17 . The system of  claim 16 , wherein the barrier member is configured to rupture above a threshold level of force. 
     
     
         18 . The system of  claim 16 , wherein the second injectable composition comprises a hydrophilic polymer selected from the group consisting of acrylate-based polymers, polyurethane-based polymers, polynorbornene-based polymer and polylactide-based polymers. 
     
     
         19 . The system of  claim 16 , wherein the second injectable composition comprises a polysaccharide. 
     
     
         20 . The system of  claim 16  wherein the delivery device is configured to be delivered through a working channel of an endoscope.

Join the waitlist — get patent alerts

Track US2024000473A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.